Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function-Reference-Cited by-同舟云学术

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function

Published:1997-04 Issue:4 Volume:26 Page:816-825
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Malesci Alberto,Tacconi Milena,Valentini Angela,Basilico Mauro,Lorenzano Elettra,Salerno Francesco

Publisher

Elsevier BV

Subject

Hepatology

Reference33 articles.

1. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action;Bauer;Life Sci,1982

2. Review: long-acting somatostatin analogues;Long;Aliment Pharmacol Ther,1987

3. The influence of a long-acting somatostatin analogue on spanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis;Wahren;Scand J Gastroenterol,1996

4. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis;Eriksson;Scand J Gastroenterol,1987

5. The effect of a long-lasting somatostatin analogue on portal and systemic haemodynamics in cirrhosis;Pringle;Aliment Pharmacol Ther,1988

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practice guidance for the use of terlipressin for liver cirrhosis–related complications;Therapeutic Advances in Gastroenterology;2022-01

2. Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study;Advances in Therapy;2020-08-28

3. Therapeutic Monitoring of Portal Pressure Lowering Drugs Using Liver Stiffness;Liver Elastography;2020

4. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension;Alimentary Pharmacology & Therapeutics;2012-03-01

5. A 3-Month Course of Long-Acting Repeatable Octreotide (Sandostatin LAR) Improves Portal Hypertension in Patients With Cirrhosis: A Randomized Controlled Study;The American Journal of Gastroenterology;2007-07